ARTICLE | Clinical News
Iroko's meloxicam meets in Phase III OA pain trial
June 12, 2014 11:32 PM UTC
Iroko Pharmaceuticals LLC (Philadelphia, Pa.) said once-daily 5 and 10 mg doses of SoluMatrix meloxicam each met the primary endpoint of reducing mean pain scores from baseline to week 12 vs. placebo ...